Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 1005

Next Previous
Drug Profile

AB 1005

Alternative Names: AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD; AB-1005; Adeno-associated-virus-GDNF-therapy-Brain Neurotherapy Bio; AMT-140; GDNF gene therapy - Brain Neurotherapy Bio; Glial cell line derived neurotrophic factor gene therapy-Brain Neurotherapy Bio

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Asklepios BioPharmaceutical; Brain Neurotherapy Bio
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • No development reported Multiple system atrophy

Most Recent Events

  • 10 Oct 2025 AskBio plans a phase II trial for Parkinson's disease in May 2026 (Intracerebral, Infusion)(NCT07215403)
  • 28 Sep 2025 No recent reports of development identified for phase-I development in Multiple system atrophy in USA (Intracerebral, Infusion)
  • 17 Sep 2025 AskBio completes enrollemnt in phase I trial of AB 1005 Multiple system atrophy in the USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top